CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
1.98
6.6%
Market Trading Hours* (UTC) Opens on Tuesday at 13:30

Mon - Fri: 13:30 - 20:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.05
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026151 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026151%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003929 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003929%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Allovir Inc ESG Risk Ratings

High Medium Low Negligible

‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 2.12
Open* 2.1
1-Year Change* -73.45%
Day's Range* 1.96 - 2.1
52 wk Range 2.42-10.29
Average Volume (10 days) 491.15K
Average Volume (3 months) 18.39M
Market Cap 325.66M
P/E Ratio -100.00K
Shares Outstanding 113.87M
Revenue N/A
EPS -1.83
Dividend (Yield %) N/A
Beta -100.00K
Next Earnings Date Nov 1, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Oct 2, 2023 1.98 -0.13 -6.16% 2.11 2.11 1.96
Sep 29, 2023 2.12 -0.04 -1.85% 2.16 2.24 2.11
Sep 28, 2023 2.19 0.00 0.00% 2.19 2.21 2.08
Sep 27, 2023 2.19 -0.06 -2.67% 2.25 2.34 2.18
Sep 26, 2023 2.25 -0.01 -0.44% 2.26 2.51 2.24
Sep 25, 2023 2.32 0.10 4.50% 2.22 2.33 2.15
Sep 22, 2023 2.26 0.07 3.20% 2.19 2.28 2.16
Sep 21, 2023 2.25 0.12 5.63% 2.13 2.32 2.10
Sep 20, 2023 2.25 0.09 4.17% 2.16 2.38 2.13
Sep 19, 2023 2.21 -0.01 -0.45% 2.22 2.22 1.89
Sep 18, 2023 2.12 -0.38 -15.20% 2.50 2.51 2.08
Sep 15, 2023 2.48 -0.18 -6.77% 2.66 2.69 2.41
Sep 14, 2023 2.68 0.22 8.94% 2.46 2.73 2.44
Sep 13, 2023 2.44 -0.21 -7.92% 2.65 2.66 2.44
Sep 12, 2023 2.64 -0.15 -5.38% 2.79 2.84 2.63
Sep 11, 2023 2.83 -0.05 -1.74% 2.88 2.91 2.76
Sep 8, 2023 2.87 0.01 0.35% 2.86 2.89 2.72
Sep 7, 2023 2.85 -0.14 -4.68% 2.99 3.00 2.83
Sep 6, 2023 3.01 -0.04 -1.31% 3.05 3.12 2.80
Sep 5, 2023 3.03 -0.14 -4.42% 3.17 3.30 3.01

AlloVir, Inc. Events

Time (UTC) Country Event
Wednesday, November 1, 2023

Time (UTC)

12:30

Country

US

Event

Q3 2023 Allovir Inc Earnings Release
Q3 2023 Allovir Inc Earnings Release

Forecast

-

Previous

-
Tuesday, February 13, 2024

Time (UTC)

13:30

Country

US

Event

Q4 2023 Allovir Inc Earnings Release
Q4 2023 Allovir Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 0 0 0 0.165 1.135
Revenue 0 0 0.165 1.135
Total Operating Expense 171.202 169.818 71.309 26.866 4.731
Selling/General/Admin. Expenses, Total 52.332 49.083 21.646 10.618 3.031
Research & Development 118.87 120.735 49.663 16.248 1.7
Operating Income -171.202 -169.818 -71.309 -26.701 -3.596
Interest Income (Expense), Net Non-Operating 1.876 1.315 1.33 2.065 0.056
Other, Net 0.351 -2.452 0.195 0.797 1.11
Net Income Before Taxes -168.975 -170.955 -69.784 -23.839 -2.43
Net Income After Taxes -168.71 -171.962 -69.784 -23.839 -2.43
Net Income Before Extra. Items -168.71 -171.962 -69.784 -23.839 -2.43
Net Income -168.71 -171.962 -69.784 -23.839 -2.43
Total Adjustments to Net Income -5.726
Income Available to Common Excl. Extra. Items -168.71 -171.962 -69.784 -23.839 -8.156
Income Available to Common Incl. Extra. Items -168.71 -171.962 -69.784 -23.839 -8.156
Diluted Net Income -168.71 -171.962 -69.784 -23.839 -8.156
Diluted Weighted Average Shares 76.6549 62.7821 61.9313 69.1735 69.1735
Diluted EPS Excluding Extraordinary Items -2.2009 -2.73903 -1.1268 -0.34463 -0.11791
Dividends per Share - Common Stock Primary Issue 0 0
Diluted Normalized EPS -2.2009 -2.73903 -1.1268 -0.34463 -0.11791
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0 0 0 0 0
Total Operating Expense 47.304 43.231 40.434 42.95 44.624
Selling/General/Admin. Expenses, Total 12.48 12.513 12.014 12.946 13.245
Research & Development 34.824 30.718 28.42 30.004 31.379
Operating Income -47.304 -43.231 -40.434 -42.95 -44.624
Interest Income (Expense), Net Non-Operating 1.516 1.325 0.898 0.668 0.162
Other, Net 0.521 0.723 0.985 0.21 -0.027
Net Income Before Taxes -45.267 -41.183 -38.551 -42.072 -44.489
Net Income After Taxes -45.267 -41.183 -38.136 -42.072 -44.639
Net Income Before Extra. Items -45.267 -41.183 -38.136 -42.072 -44.639
Net Income -45.267 -41.183 -38.136 -42.072 -44.639
Income Available to Common Excl. Extra. Items -45.267 -41.183 -38.136 -42.072 -44.639
Income Available to Common Incl. Extra. Items -45.267 -41.183 -38.136 -42.072 -44.639
Diluted Net Income -45.267 -41.183 -38.136 -42.072 -44.639
Diluted Weighted Average Shares 94.6258 93.3037 92.9798 84.9488 64.4675
Diluted EPS Excluding Extraordinary Items -0.47838 -0.44139 -0.41015 -0.49526 -0.69243
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.47838 -0.44139 -0.41015 -0.49526 -0.69243
Revenue
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 243.052 253.348 361.317 127.313 25.313
Cash and Short Term Investments 233.795 248.12 356.324 126.077 22.199
Cash & Equivalents 106.092 201.661 122.661 61.084 22.199
Short Term Investments 127.703 46.459 233.663 64.993 0
Total Receivables, Net 0.157 0.05 0.45 0.56 0.302
Accounts Receivable - Trade, Net 0 0.298 0.302
Prepaid Expenses 9.1 5.178 4.543 0.676 0.051
Other Current Assets, Total 0 2.761
Total Assets 277.079 286.594 370.821 139.422 25.319
Property/Plant/Equipment, Total - Net 32.563 31.292 9.504 12.109 0
Other Long Term Assets, Total 1.464 1.954 0 0.006
Total Current Liabilities 24.338 37.853 12.294 9.106 3.737
Accounts Payable 3.004 8.361 0.963 0.63 0.153
Accrued Expenses 21.15 26.743 10.759 8.23 0.674
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 0.184 2.749 0.572 0.246 2.91
Total Liabilities 52.56 61.328 17.757 17.798 3.737
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 28.222 23.475 5.463 8.692 0
Total Equity 224.519 225.266 353.064 121.624 21.582
Redeemable Preferred Stock 0 0 0 173.127 52.204
Common Stock 0.009 0.007 0.007 0 0
Additional Paid-In Capital 690.753 522.479 478.272 3.748 0.858
Retained Earnings (Accumulated Deficit) -465.775 -297.065 -125.103 -55.319 -31.48
Unrealized Gain (Loss) 0.068 0
Total Liabilities & Shareholders’ Equity 277.079 286.594 370.821 139.422 25.319
Total Common Shares Outstanding 93.0932 63.5659 61.9313 69.1735 69.1735
Property/Plant/Equipment, Total - Gross 33.567 31.573 9.596 12.128
Accumulated Depreciation, Total -1.004 -0.281 -0.092 -0.019
Other Equity, Total -0.468 -0.155 -0.112
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total Current Assets 212.275 243.052 272.042 176.517 206.441
Cash and Short Term Investments 202.57 233.795 264.107 172.673 201.375
Cash & Equivalents 115.698 106.092 123.834 71.093 100.206
Short Term Investments 86.872 127.703 140.273 101.58 101.169
Total Receivables, Net 0.244 0.157 0.261 0.091 0.172
Prepaid Expenses 9.461 9.1 7.674 3.753 4.894
Total Assets 244.044 277.079 293.698 199.995 231.09
Property/Plant/Equipment, Total - Net 30.427 32.563 20.07 21.769 22.818
Total Current Liabilities 24.959 24.338 20.719 21.588 18.639
Accounts Payable 4.134 3.004 4.889 5.518 4.473
Accrued Expenses 20.559 21.15 15.595 15.353 12.439
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 0.266 0.184 0.235 0.717 1.727
Total Liabilities 50.512 52.56 40.472 41.858 39.415
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 25.553 28.222 19.753 20.27 20.776
Total Equity 193.532 224.519 253.226 158.137 191.675
Common Stock 0.009 0.009 0.009 0.007 0.007
Additional Paid-In Capital 700.782 690.753 681.419 544.141 532.946
Retained Earnings (Accumulated Deficit) -506.958 -465.775 -427.639 -385.567 -340.928
Unrealized Gain (Loss)
Total Liabilities & Shareholders’ Equity 244.044 277.079 293.698 199.995 231.09
Total Common Shares Outstanding 93.428 93.0932 92.6401 64.7881 64.2641
Other Long Term Assets, Total 1.342 1.464 1.586 1.709 1.831
Other Equity, Total -0.301 -0.468 -0.563 -0.444 -0.35
Redeemable Preferred Stock 0
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -168.71 -171.962 -69.784 -23.839 -2.43
Cash From Operating Activities -142.052 -106.319 -60.811 -20.155 1.943
Cash From Operating Activities 0.723 0.189 0.073 0.019 0
Non-Cash Items 42.081 46.1 9.931 2.27 0.967
Cash Interest Paid 0 0.125 0
Changes in Working Capital -16.146 19.354 -1.031 1.395 3.406
Cash From Investing Activities -80.478 185.983 -169.497 -64.644 0
Capital Expenditures 0 -0.026 -0.235 -0.339 0
Other Investing Cash Flow Items, Total -80.478 186.009 -169.262 -64.305 0
Cash From Financing Activities 126.961 0.232 291.975 120.923 22.872
Issuance (Retirement) of Stock, Net 126.961 0.232 295.449 120.923 22.872
Net Change in Cash -95.569 79.852 61.577 36.124 24.815
Financing Cash Flow Items 0 -3.474
Foreign Exchange Effects 0 -0.044 -0.09
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -41.183 -168.71 -130.574 -88.502 -43.863
Cash From Operating Activities -32.118 -142.052 -110.481 -75.354 -46.476
Cash From Operating Activities 0.086 0.723 0.637 0.552 0.466
Non-Cash Items 9.761 42.081 32.901 22.187 10.923
Changes in Working Capital -0.782 -16.146 -13.445 -9.591 -14.002
Cash From Investing Activities 41.724 -80.478 -94.015 -55.458 -54.979
Capital Expenditures 0 0 0 0
Other Investing Cash Flow Items, Total 41.724 -80.478 -94.015 -55.458 -54.979
Foreign Exchange Effects 0 0 0 0
Net Change in Cash 9.606 -95.569 -77.827 -130.568 -101.455
Cash From Financing Activities 126.961 126.669 0.244 0
Financing Cash Flow Items 0
Issuance (Retirement) of Stock, Net 126.961 126.669 0.244
Cash Taxes Paid 0

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

AlloVir, Inc. Company profile

About Allovir Inc

AlloVir, Inc. is a late clinical-stage cell therapy company. The Company is engaged in developing allogeneic T-cell therapies to treat and prevent viral diseases. Its virus-specific T cell (VST) therapy platform enables to generate VSTs designed to restore immunity in patients with T cell deficiencies. Its product candidate includes Viralym-M (ALVR105), ALVR106, ALVR109, ALVR107 and ALVR108. Its lead product candidate, Viralym-M, is a multi- VST therapy targeting five viruses: BK virus (BKV), cytomegalovirus (CMV), adenovirus (AdV), Epstein-Barr virus (EBV), and human herpesvirus 6 (HHV-6). The ALVR106 is an allogeneic VST therapy developed to target diseases caused by four respiratory viruses: respiratory syncytial virus (RSV), influenza, parainfluenza virus (PIV), and human metapneumovirus (hMPV). Its LVR109 is an allogeneic VST therapy that targets severe acute respiratory syndrome coronavirus two (SARS-CoV-2).

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Allovir Inc revenues was not reported. Net loss increased from $69.8M to $172M. Higher net loss reflects Research and development increase from $46.1M to $100.1M (expense), Stock-based Compensation in SGA increase from $5.9M to $23.3M (expense), Stock-based Compensation in R&D increase from $3.6M to $20.6M (expense).

Industry: Bio Therapeutic Drugs

1100 Winter Street
WALTHAM
MASSACHUSETTS 02451
US

Income Statement

  • Annual
  • Quarterly

News

How to Trade The Triple Top

Welcome to Part 5 of our 7-part Power Patterns series. In this series, we'll be equipping you with the skills to trade some of the most indicative price patterns which occur on any timeframe in every market.

14:13, 27 September 2023
USA flag on the background of stock charts. Financial system in USA

Q4 lookahead: US indices starting to show signs of trouble?

US indices start to draw attention as traders focus on the outlook for Q4.

07:20, 27 September 2023

USD/JPY Climbs Towards Key Highs

USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.

11:32, 26 September 2023

EUR/USD tests key support

EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

14:32, 21 September 2023
Bank of England building

BoE leaves rates unchanged, GBP drops further as investors look for more clarity

The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

11:45, 21 September 2023
British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

GBP softer after CPI surprise, JPY focused on any further hints from Ueda

GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

12:42, 20 September 2023

How to Trade The Break & Retest

In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

11:59, 20 September 2023

People also watch

Oil - Crude

87.32 Price
-0.680% 1D Chg, %
Long position overnight fee 0.0594%
Short position overnight fee -0.0813%
Overnight fee time 21:00 (UTC)
Spread 0.030

BTC/USD

27,643.35 Price
-0.810% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 85.00

US100

14,796.10 Price
-0.290% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0039%
Overnight fee time 21:00 (UTC)
Spread 1.8

XRP/USD

0.52 Price
-1.090% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01192

Still looking for a broker you can trust?

Join the 555.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading